These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 37902028)

  • 21. Development of chalcone-O-alkylamine derivatives as multifunctional agents against Alzheimer's disease.
    Bai P; Wang K; Zhang P; Shi J; Cheng X; Zhang Q; Zheng C; Cheng Y; Yang J; Lu X; Sang Z
    Eur J Med Chem; 2019 Dec; 183():111737. PubMed ID: 31581002
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Design, synthesis and biological evaluation of rasagiline-clorgyline hybrids as novel dual inhibitors of monoamine oxidase-B and amyloid-β aggregation against Alzheimer's disease.
    Xie SS; Liu J; Tang C; Pang C; Li Q; Qin Y; Nong X; Zhang Z; Guo J; Cheng M; Tang W; Liang N; Jiang N
    Eur J Med Chem; 2020 Sep; 202():112475. PubMed ID: 32652406
    [TBL] [Abstract][Full Text] [Related]  

  • 23. N-alkylpiperidine carbamates as potential anti-Alzheimer's agents.
    Košak U; Strašek N; Knez D; Jukič M; Žakelj S; Zahirović A; Pišlar A; Brazzolotto X; Nachon F; Kos J; Gobec S
    Eur J Med Chem; 2020 Jul; 197():112282. PubMed ID: 32380361
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Novel dual inhibitors of AChE and MAO derived from hydroxy aminoindan and phenethylamine as potential treatment for Alzheimer's disease.
    Sterling J; Herzig Y; Goren T; Finkelstein N; Lerner D; Goldenberg W; Miskolczi I; Molnar S; Rantal F; Tamas T; Toth G; Zagyva A; Zekany A; Finberg J; Lavian G; Gross A; Friedman R; Razin M; Huang W; Krais B; Chorev M; Youdim MB; Weinstock M
    J Med Chem; 2002 Nov; 45(24):5260-79. PubMed ID: 12431053
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cyanobiphenyls: Novel H
    Godyń J; Zaręba P; Łażewska D; Stary D; Reiner-Link D; Frank A; Latacz G; Mogilski S; Kaleta M; Doroz-Płonka A; Lubelska A; Honkisz-Orzechowska E; Olejarz-Maciej A; Handzlik J; Stark H; Kieć-Kononowicz K; Malawska B; Bajda M
    Bioorg Chem; 2021 Sep; 114():105129. PubMed ID: 34217977
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pyridoxine-resveratrol hybrids Mannich base derivatives as novel dual inhibitors of AChE and MAO-B with antioxidant and metal-chelating properties for the treatment of Alzheimer's disease.
    Yang X; Qiang X; Li Y; Luo L; Xu R; Zheng Y; Cao Z; Tan Z; Deng Y
    Bioorg Chem; 2017 Apr; 71():305-314. PubMed ID: 28267984
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rational Design of Novel Selective Dual-Target Inhibitors of Acetylcholinesterase and Monoamine Oxidase B as Potential Anti-Alzheimer's Disease Agents.
    Xu Y; Zhang J; Wang H; Mao F; Bao K; Liu W; Zhu J; Li X; Zhang H; Li J
    ACS Chem Neurosci; 2019 Jan; 10(1):482-496. PubMed ID: 30110536
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novel AP2238-clorgiline hybrids as multi-target agents for the treatment of Alzheimer's disease: Design, synthesis, and biological evaluation.
    Zhong G; Guo J; Pang C; Su D; Tang C; Jing L; Zhang F; He P; Yan Y; Chen Z; Liu J; Jiang N
    Bioorg Chem; 2023 Jan; 130():106224. PubMed ID: 36332315
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Isoquinoline alkaloids from the roots of Zanthoxylum rigidum as multi-target inhibitors of cholinesterase, monoamine oxidase A and Aβ
    Plazas E; Hagenow S; Avila Murillo M; Stark H; Cuca LE
    Bioorg Chem; 2020 May; 98():103722. PubMed ID: 32155491
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Design, synthesis, pharmacological evaluation, QSAR analysis, molecular modeling and ADMET of novel donepezil-indolyl hybrids as multipotent cholinesterase/monoamine oxidase inhibitors for the potential treatment of Alzheimer's disease.
    Bautista-Aguilera OM; Esteban G; Bolea I; Nikolic K; Agbaba D; Moraleda I; Iriepa I; Samadi A; Soriano E; Unzeta M; Marco-Contelles J
    Eur J Med Chem; 2014 Mar; 75():82-95. PubMed ID: 24530494
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rational design, synthesis and biological evaluation of novel multitargeting anti-AD iron chelators with potent MAO-B inhibitory and antioxidant activity.
    Jiang X; Guo J; Lv Y; Yao C; Zhang C; Mi Z; Shi Y; Gu J; Zhou T; Bai R; Xie Y
    Bioorg Med Chem; 2020 Jun; 28(12):115550. PubMed ID: 32503694
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Design, synthesis, and evaluation of chalcone-Vitamin E-donepezil hybrids as multi-target-directed ligands for the treatment of Alzheimer's disease.
    Sang Z; Song Q; Cao Z; Deng Y; Zhang L
    J Enzyme Inhib Med Chem; 2022 Dec; 37(1):69-85. PubMed ID: 34894968
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer's disease: design, synthesis, biochemical evaluation, ADMET, molecular modeling, and QSAR analysis of novel donepezil-pyridyl hybrids.
    Bautista-Aguilera OM; Esteban G; Chioua M; Nikolic K; Agbaba D; Moraleda I; Iriepa I; Soriano E; Samadi A; Unzeta M; Marco-Contelles J
    Drug Des Devel Ther; 2014; 8():1893-910. PubMed ID: 25378907
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Discovery of novel hybrids containing clioquinol-1-benzyl-1,2,3,6-tetrahydropyridine as multi-target-directed ligands (MTDLs) against Alzheimer's disease.
    Li X; Li T; Zhang P; Li X; Lu L; Sun Y; Zhang B; Allen S; White L; Phillips J; Zhu Z; Yao H; Xu J
    Eur J Med Chem; 2022 Dec; 244():114841. PubMed ID: 36257284
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Design, synthesis and biological activity of novel donepezil derivatives bearing N-benzyl pyridinium moiety as potent and dual binding site acetylcholinesterase inhibitors.
    Lan JS; Zhang T; Liu Y; Yang J; Xie SS; Liu J; Miao ZY; Ding Y
    Eur J Med Chem; 2017 Jun; 133():184-196. PubMed ID: 28388521
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Donepezil + propargylamine + 8-hydroxyquinoline hybrids as new multifunctional metal-chelators, ChE and MAO inhibitors for the potential treatment of Alzheimer's disease.
    Wang L; Esteban G; Ojima M; Bautista-Aguilera OM; Inokuchi T; Moraleda I; Iriepa I; Samadi A; Youdim MB; Romero A; Soriano E; Herrero R; Fernández Fernández AP; Ricardo-Martínez-Murillo ; Marco-Contelles J; Unzeta M
    Eur J Med Chem; 2014 Jun; 80():543-61. PubMed ID: 24813882
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synthesis and evaluation of 7-substituted coumarin derivatives as multimodal monoamine oxidase-B and cholinesterase inhibitors for the treatment of Alzheimer's disease.
    Joubert J; Foka GB; Repsold BP; Oliver DW; Kapp E; Malan SF
    Eur J Med Chem; 2017 Jan; 125():853-864. PubMed ID: 27744252
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Design, Synthesis, and Pharmacological Evaluation of
    Kumar B; Dwivedi AR; Arora T; Raj K; Prashar V; Kumar V; Singh S; Prakash J; Kumar V
    ACS Chem Neurosci; 2022 Jul; 13(14):2122-2139. PubMed ID: 35797244
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Design, synthesis, and pharmacological evaluation of 2-amino-5-nitrothiazole derived semicarbazones as dual inhibitors of monoamine oxidase and cholinesterase: effect of the size of aryl binding site.
    Tripathi RKP; M Sasi V; Gupta SK; Krishnamurthy S; Ayyannan SR
    J Enzyme Inhib Med Chem; 2018 Dec; 33(1):37-57. PubMed ID: 29098902
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development of the "hidden" multi-target-directed ligands by AChE/BuChE for the treatment of Alzheimer's disease.
    Chen R; Li X; Chen H; Wang K; Xue T; Mi J; Ban Y; Zhu G; Zhou Y; Dong W; Tang L; Sang Z
    Eur J Med Chem; 2023 May; 251():115253. PubMed ID: 36921526
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.